Education
About Us
Working with TipRanks
Follow Us
Cooper Companies (COO)
NASDAQ:COO
COO Stock Chart & Stats
$83.90
-$0.81(-0.88%)
At close: 4:00 PM EST
$83.90
-$0.81(-0.88%)
Day’s Range― - ―
52-Week Range$61.78 - $100.24
Previous CloseN/A
Volume244.93K
Average Volume (3M)2.81M
Market Cap
$16.29B
Enterprise Value$16.53B
Total Cash (Recent Filing)$124.90M
Total Debt (Recent Filing)$2.48B
Price to Earnings (P/E)44.4
Beta0.73
Next Earnings
Feb 26, 2026EPS Estimate
1.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.15
Shares Outstanding195,978,030
10 Day Avg. Volume1,875,772
30 Day Avg. Volume2,812,655
Financial Highlights & Ratios
PEG Ratio-7.35
Price to Book (P/B)0.00
Price to Sales (P/S)3.42
P/FCF Ratio0.00
Enterprise Value/Market Cap1.01
Enterprise Value/Revenue4.09
Enterprise Value/Gross Profit6.10
Enterprise Value/Ebitda15.16
Forecast
1Y Price Target
$90.33Price Target Upside7.66% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering12
EPS Forecast (FY)4.52
Revenue Forecast (FY)$4.32B
Bulls Say, Bears Say
Bulls Say
Board Leadership And Strategic ReviewBoard appointment of Colleen Jay and initiation of a formal strategic review signal leadership alignment toward actions designed to enhance long-term shareholder value through divestitures, partnerships, or a sale.
Cost Savings And Cash GenerationManagement expects pretax integration savings of $50 million in FY26 and has increased its multi-year free cash flow target, indicating potential for stronger margins and cash generation to support shareholder returns.
Potential Business SeparationEvaluation of separating the Contact Lens and Women’s Health units could enable independent valuation and strategic focus for each business, potentially unlocking shareholder value.
Bears Say
Acquisition ReturnsRecent acquisitions in Women’s Health have underperformed on return on invested capital, raising doubts about deal execution and potential dilution to shareholder value.
Regulatory Risk For Key AcquisitionSignificant regulatory hurdles tied to acquiring a major contact lens business raise the prospect of mandated divestitures or prolonged approval processes that could hinder strategic progress.
Revenue Guidance ShortfallNew revenue guidance came in slightly below consensus, creating concern about near-term top-line momentum and the company's ability to meet growth expectations.
Cooper Co News
COO FAQ
What was Cooper Companies’s price range in the past 12 months?
Cooper Companies lowest stock price was $61.77 and its highest was $100.24 in the past 12 months.
What is Cooper Companies’s market cap?
Cooper Companies’s market cap is $16.29B.
When is Cooper Companies’s upcoming earnings report date?
Cooper Companies’s upcoming earnings report date is Feb 26, 2026 which is in 46 days.
How were Cooper Companies’s earnings last quarter?
Cooper Companies released its earnings results on Dec 04, 2025. The company reported $1.15 earnings per share for the quarter, beating the consensus estimate of $1.113 by $0.037.
Is Cooper Companies overvalued?
According to Wall Street analysts Cooper Companies’s price is currently Undervalued.
Does Cooper Companies pay dividends?
Cooper Companies pays a Semiannually dividend of $0.007 which represents an annual dividend yield of N/A. See more information on Cooper Companies dividends here
What is Cooper Companies’s EPS estimate?
Cooper Companies’s EPS estimate is 1.03.
How many shares outstanding does Cooper Companies have?
Cooper Companies has 195,978,030 shares outstanding.
What happened to Cooper Companies’s price movement after its last earnings report?
Cooper Companies reported an EPS of $1.15 in its last earnings report, beating expectations of $1.113. Following the earnings report the stock price went up 5.673%.
Which hedge fund is a major shareholder of Cooper Companies?
Currently, no hedge funds are holding shares in COO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cooper Co Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$90.33 (7.66% Upside)
$90.33 (7.66% Upside)
Blogger Sentiment
Bullish
COO Sentiment 70%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 26.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $1.3M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.7%
Last 30 Days ▼ 3.5%
Last 30 Days ▼ 3.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-9.52%
12-Months-Change
Fundamentals
Return on Equity
4.59%
Trailing 12-Months
Asset Growth
0.65%
Trailing 12-Months
Company Description
Cooper Companies
The Cooper Companies, Inc., together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment offers spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, myopia, ocular dryness and eye fatigues in the Americas, Europe, Middle East, Africa, and Asia Pacific. The CooperSurgical segment focuses on family and women's health care, which provides medical devices, fertility, genomics, diagnostics, and contraception to health care professionals and patients worldwide. It offers surgical and office products, including PARAGARD, uterine manipulators, retractors, closure products, point of care products, LEEP products, endosee, and illuminate and fetal pillows; fertility products and services, such as fertility consumables and equipment, and embryo options and preimplantation genetic testing. The Cooper Companies, Inc. was founded in 1958 and is headquartered in San Ramon, California.
COO Company Deck
COO Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The company's earnings call reflected a focus on strong financial performance and strategic growth initiatives. While CooperVision and the share repurchase program showed significant positive trends, challenges in certain markets, particularly in China and the fertility segment, posed some concerns.View all COO earnings summariesCOO Net sales Breakdown
67.05% CooperVision
32.95% CooperSurgical
COO Stock 12 Month Forecast
Average Price Target
$90.33
▲(7.66% Upside)
Technical Analysis
Ownership Overview
0.53% Insiders
36.79% Mutual Funds
35.25% Other Institutional Investors
1.65% Public Companies and
Individual Investors